Nahome Fisseha

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Michael J. Soileau, Jason Aldred, Kumar Budur et al. · The Lancet Neurology · 2022 · 172 citations

Advanced Parkinson, Parkinson Disease, Neurology +3

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Günter U. Höglinger, Irene Litvan, Nuno Mendonça et al. · The Lancet Neurology · 2021 · 130 citations · Full text

Clinical Trials, Progressive Supranuclear Palsy, Placebo-controlled Trial +7

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study

Hana Florian, Deli Wang, Steven E. Arnold et al. · Brain · 2023 · 119 citations · Full text

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance

Victor S.C. Fung, Jason Aldred, Martha P. Arroyo et al. · Clinical Parkinsonism & Related Disorders · 2024 · 31 citations · Full text

Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization.

Joan Busner, Gahan Pandina, SilviaZaragoza Domingo et al. · PubMed · 2021 · 11 citations · Full text